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Summary Unilamellar liposomes of dipalmitoyl-phosphatidylcholine can incorporate various porphyrins in
either the phospholipid bilayer or the internal aqueous compartment depending on the water-/lipo-solubility
of the drug. Intraperitoneal injection of the liposome-bound porphyrins to mice bearing a MS-2 fibrosarcoma
results in remarkably more efficient tumour targeting than that obtained by administration of the same
porphyrins dissolved in homogeneous aqueous solution. Moreover, also water-insoluble porphyrins can be
transported to the tumour via liposomes. Fractionation of liver and neoplastic cells indicates that the
subcellular distribution of liposome-delivered porphyrins is also dependent on their solubility properties: thus,
relatively polar porphyrins, such as tetra(4-sulfonatophenyl)porphine and uroporphyrin, are mainly recovered
from the soluble fraction, whereas hydrophobic porphyrins, such as haematoporphyrin or porphyrin esters,
preferentially partition in the cytoplasmic membrane. As a consequence, different subcellular sites can be
targeted by porphyrins and possibly photodamaged through a suitable choice of the drug-carrier system.
The interaction of porphyrins with normal and
malignant cells is the subject of intensive
investigations (see, for recent reviews, Moan et al.,
1982; Jori & Spikes, 1984). The main interest is
focused on the mechanisms of uptake and release of
haematoporphyrin IX (Hp) and its derivative
(HpD) (see Bonnet et al., 1984, for a discussion
of the chemical composition of HpD) by cells
in connection with the widespread utilisation of
these porphyrins as photodiagnostic and photo-
therapeutic agents for tumours (Dougherty, 1980).
It has been shown (Kessel, 1981) that the affinity
of porphyrins for cultured cells and their sub-
cellular distribution are dependent on their
hydro-/lipo-solubility, e.g. as expressed by their
octanol/water partition coefficient; thus, different
cellular targets can be damaged by using porphyrins
of different solubility as photosensitisers (Sandberg
& Romslo, 1981).
In this paper, we extended the latter
investigations to in vivo systems by studying the
time-dependence of the subcellular localisation of a
variety of porphyrins in liver and tumour cells of
mice breaing a MS-2 sarcoma. The porphyrins
injected were either dissolved in PBS and/or
incorporated into small unilamellar liposomes of
DPPC. We have previously shown (Jori et al.,
1983) that liposome transport of porphyrins such as
Hp yields higher endocellular concentrations of the
drug and enhances its preferential retention by
tumour cells as compared with normal cells.
Materials and methods
Chemicals
All porphyrins were obtained from Porphyrin
Products (Logan, Utah, USA) and used as received;
high pressure liquid chromatography (HPLC)
analysis showed that the Hp sample contained
5% protoporphyrin IX, 3-5% 2(4)-hydroxyethyl-
4(2)-vinyl-deuteroporphyrin IX and traces of other
unidentified porphyrin-type impurities. HpD
(Photofrin I) was kindly supplied by Prof. T.J.
Dougherty as a sterile aqueous solution, pH 7.4, at
a nominal porphyrin concentration of 2.5mgml-1.
The concentration of the other porphyrin solutions
was estimated spectrophotometrically using the
following e values (M-1 cm-1) (Marks, 1969):
Hp, 4.23 x 105 (0.25 MH2S04, 401 nm); haemato-
porphyrin IX dimethylester (HpDME) 1.75 x 105
(pyridine, 402nm); Uroporphyrin I (Up) 5.41 x 105
(0.1 MHCI, 405.5nm); Uroporphyrin I octa-
methylester (UpOMe), 2.14 x 105 (CHC13, 406nm);
tetra(4-sulfonatophenyl)porphine (TPPS) 5.26 x 105
(CH30H, 415nm). L-a-dipalmitoyl-phosphatidyl-
choline (DPPC) over 98% pure, was purchased
from Sigma Chemical Co.; Sodium dodecylsulphate
(SDS) and sucrose were analytical-grade reagents
from Merck AG.
Animals and tumour
Female mice of the BALB/c strain, 20 days old
(30-40 g body wt), random bred in our laboratory,
were used. The animals had free access to tap water
and standard dietary chow. The tumour used was
the MS-2 sarcoma, kindly supplied by Istituto
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Nazionale dei Tumori, Milan. For routine passage,
mice were injected s.c. in the dorsal region with 106
viable cells suspended in 0.1 ml of PBS; viability
was assayed by the trypan blue exclusion test. A
solid tumour developed reaching a 0.71-1.0cm
diameter on the eight day after transplantation.
Preparation ofporphyrin-liposome systems
Small unilamellar vesicles of DPPC, containing the
porphyrin in a 1:70 molar ratio to the phospholipid
were prepared immediately before use by the
procedure previously described (Jori et al., 1983).
The homogeneity of the preparations was
occasionally checked by chromatography of the
liposomal suspensions in 0.01 M phosphate buffer at
pH 7.4, containing 0.15 M NaCl, on a column
(1.2 x 130cm) of Sephacryl S-500; a mol.wt of 3.0-
3.5 x 106 was estimated for the liposomes. Electron
microscopy analysis confirmed that the liposome
preparations showed a reasonably homogeneous
size distribution, the unilamellar vesicles having a
diameter ranging between 33 and 35 nm. Prior to
use, any unbound porphyrin was removed by gel
filtration of the liposome suspension through a
column of Sephadex G-100, where the liposomes
are eluted at the void volume. The localisation of
the porphyrin in either the phospholipid bilayer or
the endoliposomal aqueous pool was established by
fluorescence emission spectroscopy (Jori et al.,
1983).
Pharmacokinetic studies
The porphyrins, either dissolved in PBS or
incorporated into unilamellar DPPC liposomes,
were injected i.p. into tumour-bearing mice at 7
days after tumour transplantation. At this time, the
tumour weight was about 70-80 mg, and increased
to 95-110mg at 10 days and to 120-140mg at 13
days after transplantation. The injected dose was
5mg prophyrin kg-' mouse body weight except in
the case of liposomal Up and TPPS, where
1.5mgkg-1 were injected: the low efficiency of Up
and TPPS incorporation into DPPC liposomes
would have required the injection of too large
volumes of liposomal suspension in order to reach
a 5mgkg-t concentration of porphyrin. At fixed
time intervals, the mice were sacrificed, and four
tissues (tumour, liver, kidneys and skin) were
rapidly removed, washed with PBS to eliminate any
surface blood, and homogenised in PBS. An aliquot
of the homogenate was used for estimation of the
porphyrin content by a spectrophotofluorimetric
assay (Jori et al., 1979) after extraction of the
porphyrin from the tissue with 2% aqueous SDS.
Control studies* indicated that at least 90% of the
porphyrin present in the tissue is extracted by this
procedure. The fluorescence data were converted
into porphyrin concentration values by
interpolation with a calibration plot built for each
porphyrin in the presence of SDS micelles. A
second aliquot of the tissue homogenate was used
for cell fractionation by sucrose discontinuous
gradient ultracentrifugation (Neville, 1976) after
osmotic lysis of the cells. Three fractions were
collected: the soluble fraction; the membrane
fraction (37% sucrose); and the particulate fraction
(41% sucrose, including the mitochondria,
lysosomes and microsomes). The porphyrin content
of each fraction was measured by the same
procedure as used for tissues and normalised to one
gram of nitrogen. The estimation of nitrogen
content was performed according to Umbreit et al.
(1959).
Fluorescence measurements
All fluorescence measurements were carried out by
a Perkin Elmer MPF 4 spectrophotofluourimeter
using quartz cuvettes of 1 cm optical path.
Excitation was performed at 400nm and the light
emitted in the 550-750nm region was recorded at a
right angle to the incident beam. In preliminary
experiments, we observed that the height of the two
fluorescence emission peaks around 620 nm and
*The complete extraction of porphyrins from tissues is
known to be a difficult process. In order to assess the
reliability of our extraction procedure, we performed some
preliminary experiments where three portions (l-100mg)
of the liver of a normal mouse were assayed for the
porphyrin content at 3h after i.p. injection of Hp
(5mgkg- body wt) by the following methods: portion I,
homogenisation with 10ml of 2% aqueous SDS followed
by 30min incubation of the homogenate with the SDS
micellar dispersion at 20°C under magnetic stirring;
portion 2, homogenisation with 10ml of 3M HC1
followed by 8h hydrolysis of the homogenate with
3 MHCI at 60°C under nitrogen in sealed vials; portion 3,
homogenisation with 7.5ml of diethylether, centrifugation
(10min; 3,000r.p.m.), collection of the ether layer,
rehomogenisation of the tissue with 7.5ml of acetic acid,
centrifugation as above specified, collection of the acetic
acid layer, extraction of the porphyrin from the combined
ether/acetic acid layers with 3 M HCI. In all cases, the Hp
content of the final solution was estimated by spectro-
photofluorimetric analysis as specified in the experimental
section. In 5 separate experiments (one mouse liver per
experiment) the Hp recoveries obtained by the three
different procedures never differed by more than 10%;
moreover, re-extraction of residual Hp from the
homogenised tissue by the same procedure yielded Hp
recoveries which were about 5-10% the amount obtained
by the first extraction.PHARMACOKINETIC PROPERTIES OF PORPHYRINS 617
680 nm, which are typical of porphyrins, is
proportional to the integrated area below the whole
emission spectrum; therefore, the sum of the
emission intensities at the two aforesaid wave-
lengths was routinely used for the calculation of
porphyrin concentration. Care was taken to keep
the absorbance of the analysed solutions lower than
0.1 at 400 nm in order to minimise artifacts due to
inner filter effects.
Results
Porphyrin-liposome interactions
Under our experimental conditions, all the
porphyrins examined underwent incorporation into
unilamellar DPPC liposomes. The spectroscopic
parameters (see Table I) suggested that Hp,
HpDME and UpOME were located as monomeric
entities in the phospholipid bilayer, which is in
agreement with the poor water-solubility of these
porphyrins. Gel filtration studies on Sephadex G-
100 columns demonstrated that the incorporation
yield was essentially 100% in the case of the two
porphyrin esters, and around 90% for Hp. On the
other hand, Up and TPPS appeared to be located
in the endoliposomal aqueous compartment; the
low incorporation yield (-5%) of the two latter
porphyrins is likely to reflect their statistical
distribution between the internal and external
aqueous pools.
The association of the porphyrin molecules with
the DPPC liposomes was very stable, as shown by
the slow rate of porphyrin leakage from the vesicles
when DPPC liposomes containing 0.04mM
porphyrin were resuspended in PBS at 37°C: under
these conditions, after 24h about 10% Hp and no
appreciable amount of HpDME were released. The
addition of 0.2mm human serum albumin had no
effect on the release of Hp and HpDME from the
DPPC liposomes. On the other hand, over 95% of
Hp bound with 0.2mm albumin in a 1:1 complex
was captured by DPPC liposomes (the phospholipid
concentration was 2.5 mgml-1).
In a few experiments, the interaction of HpD
with DPPC liposomes was also studied. As shown
in Table I, good incorporation efficiencies were
obtained; however, the spectroscopic analyses
pointed out that the liposome-bound porphyrin
material was largely heterogeneous as regards both
the localisation sites and the aggregation state.
Pharmacokinetics of aqueous and liposome-bound
haematoporphyrin
In Table II we report the recovery of Hp from
different tissues of mice bearing a MS-2 sarcoma at
various times after administration of the porphyrin
either dissolved in PBS or incorporated into
unilamellar DPPC liposomes. The data represent
the average of Hp recoveries obtained by separate
analyses of tissues from three different mice at each
time; the largest deviation from the tabulated
figures was +20%. The analyses were performed at
particularly narrow time intervals during the initial
24h, since this time period usually corresponds with
the maximal porphyrin accumulation in liver and
tumour tissues (Gomer & Dougherty, 1979; Jori et
al., 1979). On the other hand, it was not possible to
extend the investigations beyond 6 days from Hp
administration owning to the exceedingly large size
of the tumour and possible death of the animals. In
all cases, the extracted porphyrin samples exhibited
identical spectroscopic properties independently of
the location site. Previous studies (Tomio et al.,
1982) pointed out that Hp undergoes no
appreciable metabolic alteration in normal and
tumour-bearing animals. Column chromatographic
analyses of serum samples taken from mice injected
with aqueous or liposome-bound Hp were
Table I Fluorescence properties and endoliposomal localisation of various porphyrins
associated with unilamellar DPPC vesicles.
Fluorescence emission
Amax(nm)a
Liposomal Endoliposomal Incorporation
Porphyrin H20, pH 7.4 CH30H dispersion localisation yield (%)
Hp 614 625 625 Lipid bilayer >90
HpDME 622 625 Lipid bilayer 100
HpD 612 618 610-620 H6erogeneous 90
Up 617 624b 619 Aqueous pool 5
UpOME 627 627 Lipid bilayer 100
TPPS 640 648b 640 Aqueous pool 5
aThe excitation wavelength was 400nm. The porphyrin concentration was 1OpM in all
cases; bIn methanol containing 5% water.618 G. JORI et al.
Table II Recovery of hematoporphyrin (expressed as Mg porphyrin g-1 of
tissue) from selected mouse tissues at various times after i.p. injection of
5mgkg-t bodywt aqueous or liposome-bound porphyrin to mice bearing a
MS-2 fibrosarcoma.
Liver Kidneys Skin Tumour
Time Hp-aq Hp-lip Hp-aq Hp-lip Hp-aq Hp-lip Hp-aq Hp-lip
control 0.6 0.6 0.3 0.3 0.1 0.1 0.6 0.6
1 h 4.7 3.6 2.1 1.2 0.8 0.4 1.3 0.9
2h 4.0 4.2 2.3 2.5 1.3 0.4 1.8 1.1
8h 3.1 5.3 2.0 2.5 1.7 2.0 2.1 1.8
12h 2.5 4.0 1.5 2.0 3.2 1.5 2.1 2.4
24h 1.5 3.2 1.0 1.4 1.7 1.3 1.9 4.1
72h 1.1 1.3 0.7 0.9 1.9 1.0 1.7 4.7
140h 0.7 0.9 0.5 0.8 0.8 0.5 1.0 2.9
performed at various times according to the
procedure previously described (Jori et al., 1984). In
agreement with previous findings (Jori et al., 1984),
we observed that the aqueous porphyrin was
initially distributed among at least three classes of
serum proteins, viz. lipoproteins, globulins and
albumins, but was completely eliminated from the
two latter carriers within 48h: at this time, only
10% of the administered Hp was still bound with
lipoproteins, especially high-density lipoproteins.
On the other hand, less than 20% of the liposome-
bound Hp became associated with globulins and
albumins; a large fraction (70-80%) either remained
in intact liposomes or was delivered to low- and
high-density lipoproteins. The Hp-lipoprotein
complex was very stable and its serum concen-
tration decreased at a slow rate: about 35% of the
originally administered Hp was still associated with
the lipoprotein system after 48 h.
Pharmacokinetics ofvarious aqueous and
liposome-boundporphyrins
The recoveries of various porphyrins, administered
to tumour-bearing mice either dissolved in PBS or
bound with DPPC liposomes, were evaluated after
2h and 48h from injection. These time intervals
were selected since they correspond with a large
accumulation of porphyrins in most tissues (Figge
et al., 1948) and, respectively, the performance of
photodynamic therapy of tumours in clinical
applications (Dougherty, 1981). The averaged data
from three mice analysed separately at each time
(maximum deviation+ 15%) are shown in Table
III. In general, under our experimental conditions,
relatively high recoveries were obtained with all the
porphyrin samples studied. Only in the case of
liposome-bound Up and TPPS, low amounts of
porphyrin were found to be present in all tissues at
both 2h and 48h; this fact is probably a
Table III Recovery of various porphyrins (expressed as
jg porphyrins g-1 of tissue) at 2h and 48h after i.p.
injection of 5mgkg-1 bodywt aqueous or liposome-
bound drug to mice bearing a MS-2 fibrosarcoma.
Liver Tumour
Porphyrin 2h 48h 2h 48h
HpDME-lip 4.5 2.1 2.3 5.7
Up-aq 3.9 1.0 4.2 0.8
Up-lip' 0.9 1.0 1.1 1.8
UpOME-lip 3.2 1.9 1.7 3.1
TPPS-aq 4.7 2.0 5.5 3.5
TPPS-lipa 0.8 1.2 0.5 1.7
aThe injected dose was 1.5mgkg-' bodywt.
consequence of the small porphyrin concentrations
which had to be injected (see experimental section).
Once again, the spectroscopic properties of the
porphyrins extracted from the tissues were identical
with those of the uninjected porphyrins. Moreover,
as one can see from Table II, the amount of
endogenous porphyrins present in the tissues
analysed by us was too low to interfere with the
determination of the administered drugs.
In a few experiments, the pharmacokinetic
studies above described were repeated with normal
mice. In general, the recoveries of the aqueous or
liposome-bound porphyrins from li'ver, kidneys and
skin at 2h and 48h were fairly similar with those
reported in Table III, indicating that the presence
of the tumour exerts no major influence on the
uptake and release of porphyrins from normal
tissues.
Studies on the subcellular distribution ofporphyrins
in mouse hepatocytes and tumor cells
The subcellular distribution of the aqueous orPHARMACOKINETIC PROPERTIES OF PORPHYRINS 619
Table IV Subcellular distribution of various porphyrins in hepatocytes
isolated from mice bearing a MS-2 fibrosarcoma at
2h and 48h after i.p. injection of 5mgkg-1 aqueous or liposome-
bound drug. The recoveries are expressed as ng porphyrin g-I nitrogen.
Subcellularfraction
Soluble Membrane Particulate
Porphyrin 2h 48h 2h 48h 2h 48h
Hq-aq 0.35 0.17 0.19 0.40 0.07 0.10
Hp-lip 0.20 0.25 0.54 0.63 0.12 0.08
HpDME-lip 0.10 0.08 0.45 0.90 0.10 0.10
Up-aq traces traces traces
Up-lip' 0.21 0.17 0.08 0.05 0.17 0.10
UpOME-lip 0.05 0.05 0.80 0.37 0.10 0.12
TPPS-aq 0.17 0.23 0.05 0.11 0.14 0.11
TPPS-lipa 0.27 0.30 0.11 0.08 0.12 0.14
'The injected dose was 1.5mgkg-1 body wt.
Table V Subcellular distribution of various porphyrins in tumour cells
isolated from mice bearing a MS-2 fibrosarcoma at 2h and 48h after
i.p. injection of Smgkg-1 body wt aqueous or liposome-bound drug.
The recoveries are expressed as ng porphyrin g-1 nitrogen.
Subcellularfraction
Soluble Membrane Particulate
Porphyrin 2h 48h 2h 48h 2h 48h
Hp-aq 0.48 0.21 0.38 0.57 0.12 0.12
Hp-lip 0.42 0.14 0.48 0.80 0.10 0.06
HpDME-lip 0.09 0.05 0.75 0.89 0.10 0.16
Up-aq traces traces traces
Up-lipa 0.30 0.36 0.14 0.10 0.05 traces
UpOME-lip 0.12 traces 0.58 0.72 traces
TPPS-aq 0.91 0.79 0.11 0.07 0.12 0.05
TPPS-lipa 0.75 0.83 0.30 0.10 0.13 0.11
aThe injected dose was 1.5mgkg-1 body wt.
liposome-bound porphyrins in the liver and tumour
cells was estimated at 2h and 48h after drug
administration. The data of porphyrin recovery,
normalised to a standard nitrogen content for each
fraction, are reported in Table IV (liver cells) and
Table V (tumour cells), respectively.
Discussion
The pharmacokinetic studies described in this paper
confirm the preferential affinity of Hp for
neoplastic as compared with normal tissues.* The
tumour-localising properties of this prophyrin (see
*According to Dougherty (1981) the tumour-localising
properties found for some commercial samples of Hp are
associated with the presence of about 10-15% covalent
dimers of the prophyrin.
Table II) are remarkably enhanced when Hp is
administered to tumour-bearing mice in association
with unilamellar DPPC vesicles; this observation
agrees with previous findings from our laboratory
(Jori et al., 1983). Actually, although transplanted
tumours are known to contain a significant
proportion of phagocytes which may uptake the
liposomal vesicles, previous studies (Kessel & Chou,
1983; Cozzani et al., 1984, 1985) showed that
liposome-bound Hp and HpDME are accumulated
by a variety of cultured malignant cells in
remarkably larger amounts than by cultured normal
cells. Therefore, liposomal transport appears to
yield an improved loading of tumour cells with
porphyrins. This fact is probably related to the
inability of some serum proteins to extract Hp from
the phospholipid bilayer of DPPC liposomes, where
the porphyrin is located (Jori, 1985); it has been
shown that serum albumin competes with cells for620 G. JORI et al.
Hp binding and accelerates the release of Hp from
both normal and malignant cells (Cozzani et al.,
1984). Moreover, DPPC liposomes, having a phase
transition temperature of 41.5°C, exist in a quasi-
solid state at the body temperature, hence they are
internalised by cells mainly via endocytosis; as a
consequence, the liposome-incorporated drug is
released from inside the cell, probably when
liposomes are opened at the lysosome level
(Straubinger et al., 1983). Such a mechanism of Hp
delivery from the liposomes to cells may justify
both the relatively slow accumulation and the
prolonged retention of liposomal porphyrins by
tumour tissues. In particular, one should take into
consideration the stable association of liposomal
Hp with low- and high-density lipoproteins in the
serum of mice; these proteins may act as a
porphyrin source for the tumour up to at least 72h
after injection of the drug (Jori, 1985). Thus,
significant amounts of Hp are still present in the
tumour at 72h and longer times after
administration of the liposome-bound porphyrin,
and tumour/liver ratios of Hp concentration as
high as 3 are reached; on the other hand, this ratio
is constantly below or around 1 when aqueous Hp
is administered to mice bearing a MS-2
fibrosarcoma. The larger accumulation of Hp by
tumour tissues should not be accompanied by an
increase of the general cutaneous photosensitivity,
which represents one major side effect of the
photodynamic therapy of tumours (Dougherty et
al., 1983): as one can see from Table II, the skin
levels of Hp are fairly similar in the case of the
aqueous and liposomal drug.
Table III shows that, also in the case of Up and
TPPS, liposomal transport leads to a particularly
stable association of the porphyrin with the tumour
tissue. Actually, both liposomal Up and liposomal
TPPS give quite similar porphyrin levels in the
tumour between 2h and 48h after administration
to mice, whereas the concentrations of the
corresponding aqueous porphyrins in liver and
tumour undergo a substantial decrease over the
same time interval. The clearance is especially rapid
in the case of aqueous Up, probably owing to the
inability of this porphyrin to penetrate cells to any
significant extent: as shown in Tables IV and V,
only traces of aqueous Up are detected in all the
subcellular fractions from liver and tumour
examined by us. These observations may explain
the poor photosensitising efficiency displayed by
Up in vivo (Jori & Spikes, 1984). On the other
hand, the lower rate of elimination of aqueous
TPPS from tissues can be related with its significant
localisation in the endocellular regions; this is also
in agreement with the photocytotoxic effects
observed after administration of TPPS to
experimental animals (Grenan et al., 1980).
Liposome-transported TPPS shows a subcellular
distribution pattern closely similar with that found
for aqueous TPPS; hence the partitioning of this
porphyrin among the various cell compartments
appears to be independent of the delivery
mechanism. In general, the fate of porphyrins, once
released inside the cell, appears to be controlled by
their degree of hydro-/lipo-solubility. Actually,
UpOME and HpDME, which are essentially water-
insoluble, are almost exclusively recovered from the
membrane fraction at both 2h and 48h after
administration. A preferential localisation at the
level of cell membranes is also observed for Hp, a
relatively hydrophobic porphyrin. It is likely that
this class of porphyrins are embedded into lipid
cores of the membrane, thus becoming sparingly
accessible to albumin and other serum proteins;
the latter represent the usual carriers of porphyrins
in the bloodstream. As known, porphyrin-
photosensitisation of mammalian cells induces the
formation of cholesterol hydroperoxides besides
cross-linking of membrane proteins (Spikes, 1983),
although the relative weight of either photoprocess
in causing the membrane lysis is not definitely
assessed as yet.
In any case, it is apparent that liposome carriers
for porphyrins overcome the problems connected
with both the blood transport of water-insoluble
porphyrins and the hydrophobic membrane barrier
preventing the cell penetration by highly polar
porphyrins, such as Up. Therefore, the number of
porphyrins potentially employable for the photo-
dynamic therapy of tumours' is enlarged; at the
same time, the larger concentrations and longer
retention of the drug thus obtained in the
neoplastic area should determine an increased
phototherapeutic efficiency and a greater flexibility
in the definition of the porphyrin dose or in the
choice of the optimal time interval between
porphyrin administration and irradiation of the
patient. Furthermore, the possibility exists to target
different subcellular sites by selecting the porphyrin
to be transported. This should not cause large
modifications of the intrinsic efficiency of the
photosensitisation process, since most free base
porphyrins display similar photophysical properties,
including the ability to generate the cytotoxic agent
102 (Bonnett et al., 1980, 1983; Reddi et al., 1983).
On the other hand, the preferential localisation of
porphyrins in given subcellular structures can affect
the type of photodamaged targets, hence the
mechanism and kinetics of cell necrosis (Brun et al.,
1981; Sandberg & Romslo, 1981). Again, this
circumstance amplifies the potentialities of photo-
dynamic therapy, especially as regards its possible
extensions to the treatment of diseases other than
tumours (Berns et al., 1984; Venezio et al., 1985).
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